New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
|Videos|February 21, 2014
The Impact of <em>BRCA</em> Mutations in Ovarian Cancer
Author(s)Franco M. Muggia, MD
Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses the impact of BRCA mutations in ovarian cancer.
Advertisement
Clinical Pearls
Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses the impact of BRCA mutations in ovarian cancer.
- The cloning of theBRCAgenes in the early 1990s has allowed researchers to gain much insight about the biology of ovarian cancer
- BRCAgenes are involved in DNA repair
- The majority of ovarian cancers are high-grade serous, which start in the fallopian tubes, not the ovaries
- Researchers now have a better understanding of past challenges, how to guide therapeutics, and the need to focus on molecular subtypes
Advertisement
Related to this article
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Jeff Sharman, MD, discusses bispecific antibodies, CAR T-cell therapy, and targeted agents reshaping non-Hodgkin lymphoma treatment.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
IMS Day 1 Recap: Bispecific and CAR T Data Shape Myeloma Treatment
2
Rusfertide Receives NCCN Category 1 Designation in Polycythemia Vera
3
Life-Years Saved Captures Gains—and Gaps—in Blood Cancer Treatment
4
Global Experts Define Consensus Criteria for Cure in Multiple Myeloma
5